Page 31 - Boxed Warning News Today

The Company Will Host a Conference Call and Webcast on May 11, 2023, at 8:30 AM ET...

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful

QULIPTA® now the first and only oral CGRP receptor antagonist approved to prevent migraine across frequencies, including episodic and chronic Expanded...

The U.S. Food and Drug Administration approved Gamida Cell Ltd.'s Omisirge (omidubicel-onlv) cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation.

SILVER SPRING, Md., April 17, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the

Omisirge (omidubicel-onlv) is approved to quicken the recovery of neutrophils and reduce the risk of infection in patients who need stem cell transplant.

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.

FDA approves Omisirge (omidubicel-onlv), a nicotinamide modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery time of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection following stem cell transplantation.

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.